title: Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.
abstract: Developing novel combined-modality therapeutic approaches based on understanding of the involvement of redox biology in apoptosis of malignant cells is a promising approach for improving clinical responses in B-cell lymphoma and multiple myeloma. Therapeutic modalities that generate reactive oxygen species (i.e., radiation, photodynamic therapy, and specific chemotherapeutic drugs) have been shown to be selectively cytotoxic to malignant B-cells. In this review, we will discuss agents that induce apoptosis in B-cell tumors by oxidative stress. Subsequently, a novel biochemical rationale (based on fundamental differences in cancer vs. normal cell oxidative metabolism) for combining oxidative stressors with radiotherapy and chemotherapy, that may lead to designing of more effective treatment strategies for B-cell malignancies, will be discussed. Besides providing potential curative benefit, such novel therapies could also selectively target and inhibit the emergence of drug-resistance in tumor cells, which is a major determinant of treatment failure in many B-cell malignancies.
authors.affiliation: Free Radical and Radiation Biology Program, Department of Radiation Oncology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa 52242, USA. apollina-goel@uiowa.edu
authors.forename: Apollina
authors.initials: A
authors.lastname: Goel
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Spitz
authors.forename: George J
authors.initials: GJ
authors.lastname: Weiner
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology / Q000627:therapeutic use; D001897:Boronic Acids / Q000494:pharmacology / Q000627:therapeutic use; D000069286:Bortezomib; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000494:pharmacology / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D006801:Humans; D016393:Lymphoma, B-Cell / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D009101:Multiple Myeloma / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D010087:Oxides / Q000494:pharmacology / Q000627:therapeutic use; D011719:Pyrazines / Q000494:pharmacology / Q000627:therapeutic use; D011878:Radiotherapy
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D001897:Boronic Acids; D010087:Oxides; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D000077237:Arsenic Trioxide